Abstract:Background: EGFR mutation is a strong predictor of efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs) therapy in advanced non-small cell lung cancer (NSCLC). However, around 20-30 % of EGFR-mutated cases showed no response to EGFR-TKIs, suggesting that other determinants beyond EGFR mutation likely exist. This study analyzed the role of microRNAs (miRNAs) in primary resistance to EGFR-TKIs in advanced NSCLC patients with EGFR mutation.Methods: Training group: 20 advanced NSCLC patients with EGFR 19 deletion treated with first-line EGFR-TKIs were enrolled; half of them had dramatic responses while the other half had primary resistance. Matched plasma samples were collected for miRNA profiling using TaqMan low-density array (TLDA). Bioinformatics analyses were used to identify related miRNAs possibly accounted for resistance. Testing group: Quantitative reverse transcriptase PCR (qRT-PCR) was employed to detect the level of miRNA with significant differential expression in the training set. Validation group: Another cohort with EGFR 19 deletion mutations, who had dramatically different responses to EGFR-TKI, was used to validate the difference of miRNA expression between the sensitive and resistant groups using RT-PCR.Results: Training group: 153 miRNAs were found to be differentially expressed between the sensitive and resistant groups. Potential target genes were predicted with a target scan database. Twelve differentially expressed miRNAs were selected for the analysis because of their known roles in tumorigenesis of lung cancer, resistance to drugs, and regulation of EGFR pathway. Training group: three out of the 12 miRNAs (miR-21, AmiR-27a, and miR-218) were verified to have significantly higher expression (PmiR-21 = 0.004, PmiR-27a = 0.009, PmiR-218 = 0.041, respectively) in the resistant group compared to the sensitive group. Validation group: The expression levels of these three miRNAs were validated to be significantly different (P = 0.011, 0.011, 0.026, respectively) in the validation cohort (n = 34).Conclusions: Higher expression levels of miR-21, AmiR-27a, and miR-218 detected in this study suggest potential roles of these miRNAs in primary resistance to EGFR-TKI in advanced NSCLC patients with EGFR exon 19 deletion mutations. These findings need to be further confirmed in a study with a larger sample size.

In-silico Analysis of EGFR-associated Microrna Signature in Cancer.

Association of Mirna Expression and EGFR Mutation Status in Lung Adenocarcinomas.

Exploring Microrna-Mediated Alteration of EGFR Signaling Pathway in Non-Small Cell Lung Cancer Using an Mrna:Mirna Regression Model Supported by Target Prediction Databases.

Association of EGFR Exon 19 Deletion and Mirna Expression in Lung Adenocarcinomas.

Genomic sequence analysis of EGFR regulation by microRNAs in lung cancer.

Emerging Roles of MicroRNAs in EGFR-Targeted Therapies for Lung Cancer

1070 Differential Expression of MicroRNAs in Plasma of Colorectal Cancer Patients: A Potential Marker for Colorectal Cancer Screening

Mir-200C Overexpression is Associated with Better Efficacy of EGFR-TKIs in Non-Small Cell Lung Cancer Patients with EGFR Wild-Type.

Investigation of the regulation of EGF signaling by miRNAs, delving into the underlying mechanism and signaling pathways in cancer

Identification of Plasma Microrna Profiles for Primary Resistance to EGFR-TKIs in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Activating Mutation.

MicroRNA-34a/EGFR Axis Plays Pivotal Roles in Lung Tumorigenesis

Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer

Plasma Microrna Signatures to Predict Egfr-Tki Resistance in Egfr-Mutant Advanced Nsclc Patients.

MicroRNAs and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors Sensitivity in Non-Small Cell Lung Cancer

MicroRNAs targeting EGFR signalling pathway in colorectal cancer

Expression Profile of Microrna in Epithelial Cancer: Diagnosis, Classification and Prediction

Epigallocatechin-3-gallate and cancer: focus on the role of microRNAs

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell Lines

MicroRNA Expression in Esophageal Squamous Cell Carcinoma: Novel Diagnostic and Prognostic Biomarkers.

MicroRNA Signatures in Tumor Tissue Related to Angiogenesis in Non-Small Cell Lung Cancer

MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer